Antiviral therapies are associated with reduced mortality but under-utilized in patients with viral hepatocellular carcinoma: a multinational REAL-HCC study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background and Aims: Antiviral treatment can reduce mortality of viral hepatocellular carcinoma (HCC) but may be underutilized. Methods: In a multinational real-world consortium of HCC patients with hepatitis B (HBV-HCC) or C (HCV-HCC) from 16 centers (7 countries/regions), we assessed treatment rates of nucleos(t)ide analogs in HBV-HCC (2007-2023) and direct acting antivirals in HCV-HCC (2015-2023). Results: Among 3,973 HCC patients (3,186 HBV, 647 HCV, 140 HBV/HCV), 49.7% of HBV-HCC and 63.2% of HCV-HCC patients received antiviral treatment. For HBV, lower treatment rates were observed in female (41.7% vs. 51.8%), older (>60) (45.3% vs. 54.5%), noncirrhosis (41.3% vs. 56.8%), and Asia region (37.9% vs. 85.0%) patients; for HCV, lower rates in male (59.0% vs. 72.4%), cirrhosis (60.5% vs. 73.2%), and non-Asia region (58.2% vs. 69.9%) patients, all P <0.005. Child A cirrhosis and Barcelona Clinic Liver Cancer (BCLC) 0/A patients had highest treatment rates followed by Child B and C or BCLC B, C, or D for both HBV (78.6%, 48.3%, 43.8%; 59.9%, 50.9%, 36.7%, 41.0%) and HCV (68.2%, 53.3%, 38.6%; 72.5%, 53.3%, 51.9%, 30.2%), all P <0.001. Factors independently associated with lower treatment rates were: female, age>60, Asia region, noncirrhosis, and BCLC B or C (vs. 0/A) for HBV; male, age>65, Child B or C cirrhosis (vs. non-cirrhosis), and BCLC B or C for HCV. Antiviral treatment was independently associated with reduced mortality in both HBV-HCC (adjusted hazard ratio [aHR]=0.82) and HCV-HCC (aHR=0.31) patients. Conclusion: Despite survival benefits, antiviral therapies were substantially underutilized in both HBV-HCC and HCV-HCC, particularly in advanced patients.
Source: Hepatology International
Authors: Taotao Yan, Pei-Chien Tsai, Ming-Lun Yeh, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Jennifer Leong, Xiaozhong Wang, Xu Qiang, Hiroshi Abe, Takanori Suzuki, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Chung-Feng Huang, Yao-Li Chen, Ping-Yi Lin, Satoshi Yasuda, Joanne Kimiko Liu, Mayumi Maeda, Eiichi Ogawa, Cheng-Hao Tseng, Maria Buti, Philip Vutien, Yu Jun Wong, Huy Trinh, Takashi Honda, Haruki Uojima, Masaru Enomoto, Yasuhito Tanaka, Myron Schwartz, Ramsey Cheung, Ming-Lung Yu, Mindie H. Nguyen
Institutions: First Affiliated Hospital of Xi'an Jiaotong University, Stanford Medicine, Xi'an Jiaotong University, Kaohsiung Medical University, Kaohsiung Medical University Chung-Ho Memorial Hospital, Hanyang University Seoul Hospital, Hanyang University, Ogaki Municipal Hospital, E-Da Hospital, I-Shou University, Mount Sinai Health System, Xinjiang Medical University, Shinmatsudo Central General Hospital, Nagoya City University, Changhua Christian Hospital, Kyushu University, Kyushu University Hospital, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, University of Washington, SingHealth, National University of Singapore, Changi General Hospital, SingHealth Duke-NUS Academic Medical Centre, Duke-NUS Medical School, Nagoya University Hospital, Nagoya University, Kitasato University, Osaka Metropolitan University, Kumamoto University, VA Palo Alto Health Care System, Stanford University
Language: English
Topic: Hepatitis B Virus Studies
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7212219483
